San Francisco, CA
5:00 p.m. ET/2:00 p.m. PT
(877) 881-2183 (U.S.); (970) 315-0453 (int’l)
Conference ID: 2507828
Dr. Jonathan Zalevsky, Chief Research & Development Officer discusses bempegaldesleukin (NKTR-214)
We are focused on using new chemistry approaches to make better medicines to treat cancer and auto-immune disease.